EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High-throughput tracking enables systematic phenotyping and drug repurposing in C. elegans disease models

Thomas J O'Brien, Ida L Barlow, Luigi Feriani, André E X Brown iD

eLife · 2025

DOI: 10.7554/elife.92491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Thomas J O'Brien und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Sciences, Imperial College London, London, United Kingdom. Hauptthemen laut MEDLINE: Caenorhabditis elegans, Drug Repositioning, Phenotype, Disease Models, Animal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are thousands of Mendelian diseases with more being discovered weekly and the majority have no approved treatments. To address this need, we require scalable approaches that are relatively inexpensive compared to traditional drug development. In the absence of a validated drug target, phenotypic screening in model organisms provides a route for identifying candidate treatments. Success requires a screenable phenotype. However, the right phenotype and assay may not be obvious for pleiotropic neuromuscular disorders. Here, we show that high-throughput imaging and quantitative phenotyping can be conducted systematically on a panel of C. elegans disease model strains. We used CRISPR genome-editing to create 25 worm models of human Mendelian diseases and phenotyped them using a single standardised assay. All but two strains were significantly different from wild-type controls in at least one feature. The observed phenotypes were diverse, but mutations of genes predicted to have related functions led to similar behavioural differences in worms. As a proof-of-concept, we performed a drug repurposing screen of an FDA-approved compound library, and identified two compounds that rescued the behavioural phenotype of a model of UNC80 deficiency. Our results show that a single assay to measure multiple phenotypes can be applied systematically to diverse Mendelian disease models. The relatively short time and low cost associated with creating and phenotyping multiple strains suggest that high-throughput worm tracking could provide a scalable approach to drug repurposing commensurate with the number of Mendelian diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Caenorhabditis elegansDrug RepositioningPhenotypeDisease Models, AnimalHigh-Throughput Screening AssaysAnimalsGene EditingDrug Evaluation, PreclinicalHumans

Stichwörter der Autor:innen

C. elegansDrug repurposingcomputational ethologydisease modelsgeneticsgenomics

Autor:innen und Institutionen

  • Institute of Clinical Sciences, Imperial College London, London, United Kingdom.
  • MRC London Institute of Medical Sciences, London, United Kingdom.

ORCID-Profile: André E X Brown

Förderung

  • European Research Council
  • Medical Research Council

Zitieren

APA

O'Brien, T. J., Barlow, I. L., Feriani, L., & Brown, A. E. X. (2025). High-throughput tracking enables systematic phenotyping and drug repurposing in C. elegans disease models. eLife. https://doi.org/10.7554/elife.92491

Vancouver

O'Brien TJ, Barlow IL, Feriani L, Brown AEX. High-throughput tracking enables systematic phenotyping and drug repurposing in C. elegans disease models. eLife. 2025. doi:10.7554/elife.92491

BibTeX
@article{OBrien2025,
  author = {O'Brien, Thomas J and Barlow, Ida L and Feriani, Luigi and Brown, André E X},
  title = {High-throughput tracking enables systematic phenotyping and drug repurposing in C. elegans disease models},
  journal = {eLife},
  year = {2025},
  doi = {10.7554/elife.92491}
}
Kostenlos starten →